Skip to main content
CBLLCeriBell, Inc.Sell5.6·$19.55-2.25%
Open full analysis

CeriBell, Inc. (CBLL) Stock Analysis

Breakout setup

SellModerate Confidence

Healthcare · Medical Devices

Sell if holding. Engine safety override at $19.55: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable,... Read more

$19.55+19.5% A.UpsideScore 5.6/10#25 of 64 Medical Devices
QualityF-score6 / 9FCF yield-3.95%
Stop $18.18Target $23.37(analyst − 13%)A.R:R 1.5:1
Analyst target$26.86+37.4%7 analysts
$23.37our TP
$19.55price
$26.86mean
$32

Sell if holding. Engine safety override at $19.55: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Score 5.6/10, moderate confidence.

Passes 7/8 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: aggressive.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Aug 4, 202631d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.2 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)-17.8
Mkt Cap$742M
EV/EBITDA-9.8
Profit Mgn-63.5%
ROE-37.5%
Rev Growth29.3%
Beta
DividendNone
Rating analysts14

Quality Signals

Piotroski F6/9MoatNarrow

Options Flow

IV98%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.8
Value Rank
1.9
Growth Rank
8.4
Industry growth leader

Unprofitable operations — net margin -63.5%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Rule Of 40
3.0
Current Ratio
5.0
Piotroski F
6.7
Moat
7.2
Gross Margin
10.0
Cash-burning: FCF -31% of revenueRule of 40: -2 (fail)
GatesINSIDER 0.37%=HEAVYMomentum 6.8>=5.5A.R:R 1.5 ≥ 1.5No SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 31d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Aggressive
RSI
62 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $17.07Resistance $20.76

Price Targets

$18
$23
A.Upside+19.5%
A.R:R1.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.2 < 4.0)
! Insider activity: 0.37%=heavy

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-04 (31d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CBLL stock a buy right now?

Sell if holding. Engine safety override at $19.55: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Prior stop was $18.18. Score 5.6/10, moderate confidence.

What is the CBLL stock price target?

Take-profit target: $23.37 (+19.5% upside). Prior stop was $18.18. Stop-loss: $18.18.

What are the risks of investing in CBLL?

Quality below floor (3.2 < 4.0).

Is CBLL overvalued or undervalued?

CeriBell, Inc. trades at a P/E of N/A (forward -17.8). TrendMatrix value score: 6.5/10. Verdict: Sell.

What do analysts say about CBLL?

14 analysts cover CBLL with a consensus score of 4.4/5. Average price target: $27.

What does CeriBell, Inc. do?CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel...

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.

Related stocks: DCTH (Delcath Systems, Inc.) · BWAY (Brainsway Ltd.) · TCMD (Tactile Systems Technology, Inc) · ATEC (Alphatec Holdings, Inc.) · MOBI (Mobia Medical, Inc.)
Home Stocks CBLL

Latest news

No recent news